Our host, Richard Sokolov, Executive Director and co-founder of IDE Group, speaks with Dr Alan Taylor, Executive Chairman of Clarity Pharmaceuticals.

About the Episode

Richard and Alan discuss advice on capital raising, the importance of having skin in the game, why intellectual property is so important in life sciences, how Clarity went from two provisional patents to biggest IPO on the ASX, and many more topics.

About Dr Alan Taylor and Clarity Pharmaceuticals

Alan is an expert on capital raising with 15 years of investment banking experience. Before joining Clarity, he was an Executive Director and shareholder of Inteq Limited, a boutique Australian investment bank. Alan has significant experience in capital raisings and mergers&acquisitions and has been involved in approximately $2 billion worth of transactions.

He joined Clarity when there was only a single founder and two provisional patents in 2013 and has recently led the Company through the largest ever biotechnology IPO on the Australian Securities Exchange, raising $92 million at a capitalisation of $358 million. Since joining Clarity, Alan has led over $140 million of capital raisings for the company.

Clarity is focused on theranostics, a field that combines therapy and diagnostics. It is developing Targeted Copper Theranostic (TCT) products, which allow copper isotopes to be used in the diagnosis and treatment of a range of cancers, including prostate and breast cancers, as well as rare and orphan cancer indications such as neuroblastoma - a childhood cancer that begins most often in the nerve cells outside of brain of infants and children younger than 5 years old.

About the BBFH Series

The BBFH series is a series of interviews with Founders, Professors, Executives, and other leaders of the Australian startup community. Together with our guests, we explore and analyse the drivers and challenges of the healthcare startup community here in Australia and discuss their unique journeys and stories.

Chapters/Timestamps

0:00 Introduction

0:58 Clarity Pharmaceuticals’ story

3:06 Alan’s story at Clarity

5:38 Skin in the game as a leader

7:33 Why purpose is important

10:30 Alan’s story and why losing is important

20:25 Why Intellectual Property in Medtech/LifeSciences is important

24:45 Patent/IP lifespan and strategy

28:05 Enthusiasm and challenging each other

30:10 Advice on Capital Raising

34:00 Bringing your shareholders along

35:50 The Dark Side and trying to find the right people to hang out with

37:50 BBFH, sharing knowledge and the Australian startup community

40:34 Why startups are incredible hard

41:30 Progress during difficult times  

44:55 How the adoption of science inspires future generations

 

Links

Website:  https://www.idegroup.com.au/videos-podcasts

Website BBFH Challenge: https://www.bbfhchallenge.com/

LinkedIn: https://www.linkedin.com/company/ide-/

Twitter: https://twitter.com/ide_group  

Facebook: https://www.facebook.com/IDEGroupAU/ 

Instagram: https://www.instagram.com/ide.group/  

Our host, Richard Sokolov, Executive Director and co-founder of IDE Group, speaks with Dr Alan Taylor, Executive Chairman of Clarity Pharmaceuticals.
About the Episode
Richard and Alan discuss advice on capital raising, the importance of having skin in the game, why intellectual property is so important in life sciences, how Clarity went from two provisional patents to biggest IPO on the ASX, and many more topics.
About Dr Alan Taylor and Clarity Pharmaceuticals
Alan is an expert on capital raising with 15 years of investment banking experience. Before joining Clarity, he was an Executive Director and shareholder of Inteq Limited, a boutique Australian investment bank. Alan has significant experience in capital raisings and mergers&amp;acquisitions and has been involved in approximately $2 billion worth of transactions.
He joined Clarity when there was only a single founder and two provisional patents in 2013 and has recently led the Company through the largest ever biotechnology IPO on the Australian Securities Exchange, raising $92 million at a capitalisation of $358 million. Since joining Clarity, Alan has led over $140 million of capital raisings for the company.
Clarity is focused on theranostics, a field that combines therapy and diagnostics. It is developing Targeted Copper Theranostic (TCT) products, which allow copper isotopes to be used in the diagnosis and treatment of a range of cancers, including prostate and breast cancers, as well as rare and orphan cancer indications such as neuroblastoma - a childhood cancer that begins most often in the nerve cells outside of brain of infants and children younger than 5 years old.
About the BBFH Series
The BBFH series is a series of interviews with Founders, Professors, Executives, and other leaders of the Australian startup community. Together with our guests, we explore and analyse the drivers and challenges of the healthcare startup community here in Australia and discuss their unique journeys and stories.
Chapters/Timestamps
0:00 Introduction
0:58 Clarity Pharmaceuticals&rsquo; story
3:06 Alan&rsquo;s story at Clarity
5:38 Skin in the game as a leader
7:33 Why purpose is important
10:30 Alan&rsquo;s story and why losing is important
20:25 Why Intellectual Property in Medtech/LifeSciences is important
24:45 Patent/IP lifespan and strategy
28:05 Enthusiasm and challenging each other
30:10 Advice on Capital Raising
34:00 Bringing your shareholders along
35:50 The Dark Side and trying to find the right people to hang out with
37:50 BBFH, sharing knowledge and the Australian startup community
40:34 Why startups are incredible hard
41:30 Progress during difficult times &nbsp;
44:55 How the adoption of science inspires future generations
&nbsp;
Links
Website:&nbsp; <a href="https://www.idegroup.com.au/videos-podcasts">https://www.idegroup.com.au/videos-podcasts</a>
Website BBFH Challenge: <a href="https://www.bbfhchallenge.com/">https://www.bbfhchallenge.com/</a>
LinkedIn: <a href="https://www.linkedin.com/company/ide-/">https://www.linkedin.com/company/ide-/</a>
Twitter: <a href="https://twitter.com/ide_group">https://twitter.com/ide_group</a>&nbsp;&nbsp;
Facebook: <a href="https://www.facebook.com/IDEGroupAU/">https://www.facebook.com/IDEGroupAU/</a>&nbsp;
Instagram: <a href="https://www.instagram.com/ide.group/">https://www.instagram.com/ide.group/</a> &nbsp;

The Building Better Futures for Health (BBFH) Series is a series of interviews with founders, professors, executives, and other leaders of the Australian startup community. Together with our guests, we explore and analyse the drivers and challenges of the healthcare startup community in Australia and talk about their unique journeys and stories. 

The Building Better Futures for Health (BBFH) Series is a series of interviews with founders, professors, executives, and other leaders of the Australian startup community. Together with our guests, we explore and analyse the drivers and challenges of the healthcare startup community in Australia and talk about their unique journeys and stories.&nbsp;

Building Better Futures for Health Series

IDE’s BBFH Series, hosted by IDE Group, is a series of interviews with former winners, judges and contestants of the annual Building Better Futures for Health (BBFH) Challenge.

The BBFH Challenge invites entrepreneurs, researchers and industry professionals worldwide to apply and receive up to $30,000 worth of product development, commercialisation and entrepreneurial support from IDE Group, bringing Medtech ideas to life and kick-starting the journey to commercialisation.

BBFH provides finalists and winners with the unique opportunity to obtain advice, mentorship, and financial guidance from IDE and the selected judging panel. Collectively they have access to a cross-functional team of entrepreneurs, scientists, designers, engineers, and clinical professionals, bringing an established network of knowledge, experiences, and connections in the medical technology field.

IDE&rsquo;s BBFH Series, hosted by IDE Group, is a series of interviews with former winners, judges and contestants of the annual Building Better Futures for Health (BBFH) Challenge.
The BBFH Challenge invites entrepreneurs, researchers and industry professionals worldwide to apply and receive up to $30,000 worth of product development, commercialisation and entrepreneurial support from IDE Group, bringing Medtech ideas to life and kick-starting the journey to commercialisation.
BBFH provides finalists and winners with the unique opportunity to obtain advice, mentorship, and financial guidance from IDE and the selected judging panel. Collectively they have access to a cross-functional team of entrepreneurs, scientists, designers, engineers, and clinical professionals, bringing an established network of knowledge, experiences, and connections in the medical technology field.

Advertisement